Target repurposing for neglected diseases.
暂无分享,去创建一个
[1] Tom Blundell,et al. A second front against AIDS , 1989, Nature.
[2] W. M. Sanders,et al. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.
[3] F. Kuzoe. Current situation of African trypanosomiasis. , 1993, Acta tropica.
[4] I B Duncan,et al. Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.
[5] M. Palmisano,et al. Percutaneous Absorption and Pharmacokinetics of Eflornithine HC®l 13.9% Cream in Women with Unwanted Facial Hair , 2001, Journal of clinical pharmacology.
[6] John P. Overington,et al. Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.
[7] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[8] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[9] R. Mortara,et al. The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum--new tools for designing specific inhibitors. , 2009, Biochemical and biophysical research communications.
[10] James R. Brown,et al. Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery , 2011, BMC Evolutionary Biology.
[11] L J Davis,et al. Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Fairlamb. Metabolic pathway analysis in trypanosomes and malaria parasites. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[13] N. Grishin,et al. X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine. , 1999, Biochemistry.
[14] J. Dimmock,et al. Potential role of N-myristoyltransferase in cancer. , 2007, Progress in lipid research.
[15] P. Darke,et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. , 1994, Journal of medicinal chemistry.
[16] J. Beavo,et al. Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents. , 2007, Molecular interventions.
[17] S. Kunz,et al. The Trypanosoma brucei cAMP phosphodiesterases TbrPDEBl and TbrPDEB2: flagellar enzymes that are essential for parasite virulence , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[18] J. Beavo,et al. Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[19] N. Georgopapadakou. Antifungals targeted to protein modification: focus on protein N-myristoyltransferase , 2002, Expert opinion on investigational drugs.
[20] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[21] Ian H. Gilbert,et al. N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.
[22] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[23] Els Torreele,et al. Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.
[24] K. Gull. The cell biology of parasitism in Trypanosoma brucei: insights and drug targets from genomic approaches? , 2002, Current pharmaceutical design.
[25] B. Dunn,et al. Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.
[26] J. Gordon,et al. The Biology and Enzymology of ProteinN-Myristoylation* 210 , 2001, The Journal of Biological Chemistry.
[27] H. Mett,et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine , 1997, Antimicrobial agents and chemotherapy.
[28] C. Chong,et al. New uses for old drugs , 2007, Nature.
[29] Minyong Li,et al. Chemical Validation of Phosphodiesterase C as a Chemotherapeutic Target in Trypanosoma cruzi, the Etiological Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.
[30] Solomon Nwaka,et al. Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.
[31] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[32] Eileen Kraemer,et al. PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..
[33] D. Goulding,et al. Myristoyl-CoA:Protein N-Myristoyltransferase, an Essential Enzyme and Potential Drug Target in Kinetoplastid Parasites* , 2003, The Journal of Biological Chemistry.
[34] P. McCann,et al. Polyamine metabolism: a potential therapeutic target in trypanosomes. , 1980, Science.
[35] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Périé,et al. Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. , 2002, Current topics in medicinal chemistry.
[37] D. Norbeck,et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.
[38] L. Marton,et al. Polyamines as targets for therapeutic intervention. , 1995, Annual review of pharmacology and toxicology.
[39] R. Zoraghi,et al. The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei , 2002, Proceedings of the National Academy of Sciences of the United States of America.